<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950987</url>
  </required_header>
  <id_info>
    <org_study_id>11-200</org_study_id>
    <nct_id>NCT02950987</nct_id>
  </id_info>
  <brief_title>Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes</brief_title>
  <official_title>Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating Whole Body MRI as a possible screening tool to diagnose cancer for&#xD;
      people with LFS and other inherited cancer predisposition syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals who carry the TP53 mutation have a higher risk of developing different types of&#xD;
      cancer over their lifetimes. This gene has been associated with Li Fraumeni syndrome in some&#xD;
      families, but not all families that have cancer histories consistent with Li Fraumeni&#xD;
      syndrome will have the mutation. Currently, there is no standard method of monitoring LFS&#xD;
      carriers, family members, or others individuals with cancer predisposition syndromes to&#xD;
      detect cancers in the early stages, when they may be more easily treated.&#xD;
&#xD;
      The main aim of the study is to test a relatively new medical technology called Whole Body&#xD;
      Magnetic Resonance Imaging (MRI), in patients with these syndromes, to see if cancers can be&#xD;
      detected at an early stage which may, in turn, allow for more effective treatment. The&#xD;
      investigators have chosen Whole Body MRI scanning because this scan allows doctors to look at&#xD;
      the entire body in one examination. By using this technology, participants are not exposed to&#xD;
      radiation, which is of particular importance for individuals who have a higher cancer risk&#xD;
      due to a diagnosis of LFS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Return of pediatric and adult patients with Li Fraumeni Syndrome year-after-year for 4 annual scans.</measure>
    <time_frame>4 years</time_frame>
    <description>Successful return of patients for four annual scans will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return of pediatric and adult patients with other cancer predisposition syndromes year-after-year for 4 annual scans.</measure>
    <time_frame>4 years</time_frame>
    <description>Successful return of patients for four annual scans will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of prevalent and incident cancers on WB-MRI in pediatric and adult patients with Li Fraumeni and other inherited cancer predisposition syndromes.</measure>
    <time_frame>3 years</time_frame>
    <description>Tabulation of all follow-up imaging studies, biopsies, and cancer diagnoses will be pursued.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of prevalent and incident cancers on additional screening studies in pediatric and adult patients with Li Fraumeni and other inherited cancer predisposition syndromes.</measure>
    <time_frame>3 years</time_frame>
    <description>Tabulation of all follow-up imaging studies, biopsies, and cancer diagnoses will be pursued.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Li-Fraumeni Syndrome</condition>
  <arm_group>
    <arm_group_label>Whole Body MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnetic resonance imaging will be performed on participants&#xD;
Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Whole Body MRI</intervention_name>
    <arm_group_label>Whole Body MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults&#xD;
&#xD;
          -  Individuals greater than or equal to 18 years of age.&#xD;
&#xD;
          -  Individuals with &quot;Li Fraumeni Syndrome&quot; defined as one of the following:&#xD;
&#xD;
               -  Carriers of a germline p53 mutation&#xD;
&#xD;
               -  Members of families meeting classic LFS criteria by family history without an&#xD;
                  identifiable p53 mutation&#xD;
&#xD;
               -  Obligate carrier by pedigree (these individuals can be offered testing but are&#xD;
                  still eligible if they defer). The following examples describe &quot;obligate carriers&#xD;
                  by pedigree.&quot;&#xD;
&#xD;
          -  A child of a parent with known p53 mutation that is diagnosed with cancer&#xD;
&#xD;
          -  An individual with a sibling and a child who are p53 positive -OR-&#xD;
&#xD;
          -  Individuals with an inherited cancer predisposition syndrome as defined by one of the&#xD;
             following:&#xD;
&#xD;
               -  Hereditary Retinoblastoma with a germline Rb mutation&#xD;
&#xD;
               -  Diagnosis of Hereditary Paraganglioma/Pheochromocytoma Syndrome with a germline&#xD;
                  SDH mutation&#xD;
&#xD;
               -  Diagnosis of Multiple Endocrine Neoplasia, Type 1 or 2, with a germline MEN&#xD;
                  mutation&#xD;
&#xD;
               -  New diagnosis of opsoclonus-myoclonus with a negative cancer work-up upon&#xD;
                  presentation of symptoms&#xD;
&#xD;
               -  Familial Neuroblastoma with a germline ALK mutation&#xD;
&#xD;
               -  Rapid-onset Obesity with Hypothalamic dysfunction, Hypoventilation and Autonomic&#xD;
                  Dysregulation (ROHHAD syndrome) or Congenital central hypoventilation syndrome&#xD;
                  (CCHS) with or without a germline PHOX 2B mutation&#xD;
&#xD;
               -  Von Hippel-Lindau with a VHL mutation&#xD;
&#xD;
               -  Women with an abnormal cell-free DNA test (i.e. a non-invasive prenatal test&#xD;
                  (NIPT) to detect chromosomal abnormalities) and no cancer diagnosis&#xD;
&#xD;
               -  Other rare cancer predisposition syndromes at the discretion of the treating&#xD;
                  physician and study physicians&#xD;
&#xD;
          -  NOTE: Individuals with any of the above-listed cancer predisposition syndromes (apart&#xD;
             from Li Fraumeni syndrome) are likewise eligible in the absence of a known mutation if&#xD;
             they are an obligate carrier by pedigree.&#xD;
&#xD;
          -  Individuals can have a prior history of cancer; these individuals must be in stable&#xD;
             remission and at least 6 months out from the completion of surgery/radiation\&#xD;
             therapy/chemotherapy.&#xD;
&#xD;
          -  Individual cases can be reviewed with the institutional principal investigator.&#xD;
&#xD;
          -  Individuals not pregnant at enrollment. Female subjects of childbearing potential will&#xD;
             undergo a pregnancy test prior to imaging.&#xD;
&#xD;
          -  Individuals able to give informed consent or a signature from a designated health care&#xD;
             proxy or legal guardian.&#xD;
&#xD;
        Children&#xD;
&#xD;
          -  Individuals who are less than 18 years of age&#xD;
&#xD;
          -  Individuals with &quot;Li Fraumeni Syndrome&quot; defined as one of the following:&#xD;
&#xD;
               -  Carriers of a germline p53 mutation OR&#xD;
&#xD;
               -  Members of families meeting classic LFS criteria by family history without an&#xD;
                  identifiable p53 mutation OR&#xD;
&#xD;
               -  Obligate carrier by pedigree (these individuals can be offered testing but are&#xD;
                  still eligible if they defer). The following examples describe &quot;obligate carriers&#xD;
                  by pedigree.&quot;&#xD;
&#xD;
          -  A child of a parent with known p53 mutation that is diagnosed with cancer&#xD;
&#xD;
          -  An individual with a sibling and a child who are p53 positive -OR-&#xD;
&#xD;
          -  Individuals with an inherited cancer predisposition syndrome as defined by one of the&#xD;
             following:&#xD;
&#xD;
               -  Hereditary Retinoblastoma with a germline Rb mutation&#xD;
&#xD;
               -  Diagnosis of Hereditary Paraganglioma/Pheochromocytoma Syndrome with a germline&#xD;
                  SDH mutation&#xD;
&#xD;
               -  Diagnosis of Multiple Endocrine Neoplasia, Type 1 or 2, with a germline MEN&#xD;
                  mutation&#xD;
&#xD;
               -  New diagnosis of opsoclonus-myoclonus with a negative cancer work-up upon&#xD;
                  presentation of symptoms&#xD;
&#xD;
               -  Familial Neuroblastoma with a germline ALK mutation&#xD;
&#xD;
               -  Rapid-onset Obesity with Hypothalamic dysfunction, Hypoventilation and Autonomic&#xD;
                  Dysregulation (ROHHAD syndrome) or Congenital central hypoventilation syndrome&#xD;
                  (CCHS) with or without a germline PHOX 2B mutation&#xD;
&#xD;
               -  Von Hippel-Lindau with a VHL mutation&#xD;
&#xD;
               -  Other rare cancer predisposition syndrome at the discretion of the treating&#xD;
                  physician and study physicians&#xD;
&#xD;
          -  NOTE: Individuals with any of the above-listed cancer predisposition syndromes (apart&#xD;
             from Li Fraumeni syndrome) are likewise eligible in the absence of a known mutation if&#xD;
             they are an obligate carrier by pedigree.&#xD;
&#xD;
          -  Individuals can have a prior history of cancer; these individuals must be in stable&#xD;
             remission and at least 6 months out from the completion of surgery/radiation&#xD;
             therapy/chemotherapy. Individual cases can be reviewed with the institutional&#xD;
             principal investigator.&#xD;
&#xD;
          -  Individuals not pregnant at enrollment. Female subjects of childbearing potential will&#xD;
             undergo a pregnancy test prior to imaging.&#xD;
&#xD;
          -  Signed document of informed consent completed by the parent or legal guardian&#xD;
&#xD;
          -  Signed document of assent obtained if child â‰¥10 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Adults and Children&#xD;
&#xD;
          -  Active cancer or metastatic disease, except in the case of Stage 0 Chronic Lymphocytic&#xD;
             Leukemia or nonmelanoma skin cancer.&#xD;
&#xD;
          -  Patients with a contraindication to sedation or general anesthesia&#xD;
&#xD;
          -  Patients with a metal heart valve, surgical clips, a pacemaker or any other indwelling&#xD;
             metal device that might interfere with MRI&#xD;
&#xD;
          -  Females who are pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison O'Neill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison O'Neill, MD</last_name>
    <phone>617-632-4202</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison O'Neill, MD</last_name>
      <phone>617-632-4202</phone>
    </contact>
    <investigator>
      <last_name>Allison O'Neill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Friedman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Allison O'Neill</investigator_full_name>
    <investigator_title>Instructor, Pediatric Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>Li-Fraumeni Syndrome (LFS)</keyword>
  <keyword>Cancer Predisposition Syndromes</keyword>
  <keyword>LFS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Li-Fraumeni Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

